KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

West Pharmaceutical Services (WST) Operating Leases (2019 - 2025)

Historic Operating Leases for West Pharmaceutical Services (WST) over the last 7 years, with Q3 2025 value amounting to $94.9 million.

  • West Pharmaceutical Services' Operating Leases fell 714.29% to $94.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $94.9 million, marking a year-over-year decrease of 714.29%. This contributed to the annual value of $81.8 million for FY2024, which is 319.53% down from last year.
  • Latest data reveals that West Pharmaceutical Services reported Operating Leases of $94.9 million as of Q3 2025, which was down 714.29% from $100.7 million recorded in Q2 2025.
  • Over the past 5 years, West Pharmaceutical Services' Operating Leases peaked at $106.1 million during Q1 2023, and registered a low of $61.5 million during Q3 2021.
  • In the last 5 years, West Pharmaceutical Services' Operating Leases had a median value of $93.0 million in 2022 and averaged $88.3 million.
  • Per our database at Business Quant, West Pharmaceutical Services' Operating Leases plummeted by 1189.11% in 2021 and then soared by 4761.9% in 2022.
  • West Pharmaceutical Services' Operating Leases (Quarter) stood at $63.0 million in 2021, then soared by 47.62% to $93.0 million in 2022, then fell by 9.14% to $84.5 million in 2023, then fell by 3.2% to $81.8 million in 2024, then grew by 16.01% to $94.9 million in 2025.
  • Its Operating Leases was $94.9 million in Q3 2025, compared to $100.7 million in Q2 2025 and $100.6 million in Q1 2025.